Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23625387 | 1.00 | PIK3CA (0.38) | PIK3CADYRK1ADYRK2DYRK1BKDM1A | |
| SCHEMBL26038969 | 0.93 | CHRM2 (0.38) | PIK3CADYRK1ADYRK2DYRK1BKDM1A | |
| SCHEMBL23625408 | 0.93 | PIK3CA (0.37) | PIK3CADYRK1ADYRK2DYRK1BKDM1A | |
| SCHEMBL10254340 | 0.84 | RAB9A (0.45) | KDM1AMAOAMAOBRAB9AKCNH2 | |
| SCHEMBL23645657 | 0.84 | TDP1 (0.42) | RAB9ANPC1 | |
| SCHEMBL24499851 | 0.80 | TDP1 (0.39) | RAB9ANPC1 | |
| SCHEMBL8276391 | 0.76 | CTNNB1 (0.43) | DYRK1ADYRK1BKDM1AMAOAMAOB | |
| SCHEMBL23625404 | 0.73 | ALDH1A1 (0.33) | NPC1 | |
| SCHEMBL22423823 | 0.73 | TDP1 (0.49) | MAOAMAOBRAB9ANPC1 | |
| SCHEMBL22423829 | 0.73 | TDP1 (0.49) | MAOAMAOBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | ASCENEURON SA (CH) | 2023-08-22 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | PIK3CA 4589/4885DYRK1A 1325/4885DYRK2 1092/4885 |
| US-20220143042-A1 | FUSED GLYCOSIDASE INHIBITORS | BACE1, ENGASE, GBA3 | PIK3CA 4302/4885DYRK1A 2438/4885DYRK2 2313/4885 |
| US-20210213005-A1 | PYRROLIDINE GLYCOSIDASE INHIBITORS | PREP, GAA, DNPEP | PIK3CA 3593/4885DYRK1A 2151/4885DYRK2 2467/4885 |
| US-11731972-B2 | Spiro compounds as glycosidase inhibitors | GLA, BACE1, GAA | PIK3CA 3285/4885DYRK1A 1463/4885DYRK2 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.